BACKGROUND Invasive meningococcal disease (IMD) is a major cause of bacterial meningitides and septicaemia. This study shows the results of the laboratory-based surveillance of IMD in Belgium over the period 1997-2012. METHODS The results are based on microbiological and molecular laboratory surveillance of 2997 clinical isolates of N. meningitides received by the Belgian Meningococcal Refere...

BACKGROUND Invasive meningococcal disease (IMD) caused by serogroup B is the last major serogroup in Canada to become vaccine-preventable. The anticipated availability of vaccines targeting this serogroup prompted an assessment of the epidemiology of serogroup B disease in Ontario, Canada. METHODS We retrieved information on confirmed IMD cases reported to Ontario's reportable disease databas...

In September 2015, 4CMenB meningococcal vaccine was introduced into the United Kingdom infant immunization program without phase 3 trial information. Understanding the effect of this program requires enhanced surveillance of invasive meningococcal disease (IMD) Neisseria meningitidis isolates and comparison with prevaccination isolates. Bexsero Antigen Sequence Types (BASTs) were used to analyz...

the absence of cerebrospinal fluid (csf) pleocytosis in invasive meningococcal disease (imd) has been associated with an increased risk of death. it is unknown whether patients who lack a cellular response to central nervous system (cns) infection are at the same risk of adverse outcome as patiens without cns infection. to determine the frequency of presentation and outcome of three groups of c...

BACKGROUND In order to inform meningococcal disease prevention strategies, we analysed the epidemiology of invasive meningococcal disease (IMD) in the province of Quebec, Canada, 10 years before and 10 years after the introduction of serogroup C conjugate vaccination. METHODOLOGY IMD cases reported to the provincial notifiable disease registry in 1991-2011 and isolates submitted for laborator...

In 2007, a European survey identified variation in country policies on public health management of invasive meningococcal disease (IMD). In 2009-10, the European Centre for Disease Prevention and Control (ECDC) published evidence-based guidance on IMD. We therefore surveyed again European countries to describe policies for managing IMD cases and contacts in 2013. We asked national IMD public he...

OBJECTIVES To explore understanding, perceptions and feelings about meningococcal disease in members of higher risk groups. To explore what people say are the most important health messages and communication preferences about invasive meningococcal disease (IMD). METHODS Three focus groups and two semistructured interviews were conducted with people at higher risk of IMD in Hunter New England...

Neisseria meningitidis serogroup B (MnB) is a leading cause of bacterial meningitis; however, MnB is most commonly associated with asymptomatic carriage in the nasopharyngeal cavity, as opposed to the disease state. Two vaccines are now licensed for the prevention of MnB disease; a possible additional benefit of these vaccines could be to protect against disease indirectly by disrupting nasopha...

Since 2003, the Australian government has funded a conjugate serogroup C meningococcal vaccine for those aged over 1 year and born since 1 January 1984. This summary of the epidemiology of invasive meningococcal disease (IMD) in Queensland assesses the effect that the vaccination program has had on IMD notifications. In Queensland, IMD cases are notified to the Notifiable Conditions System by c...

Little information is available publicly on invasive meningococcal disease (IMD) in elderly people in Australia. This study analysed IMD notifications data from New South Wales between 1993 and 2012 to determine the distribution of IMD among people aged 65 years and older and to describe the characteristics of IMD in this age group compared to younger age groups with respect to notification tre...